Emmanuel Antonarakis, MD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Amgen
    Date added:
    Date updated:
    11/09/2023
    Relationship end date:
    12/09/2022
  • Attribution:
    Self
    Type of financial relationship:
    Intellectual Property Interest (Oncology)
    Ineligible company:
    QIAGEN
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    AstraZeneca
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Merck
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Sanofi
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Janssen
    Date added:
    Date updated:
    11/09/2023

Pages

Return to PARPi: Precision Medicine in Advanced Prostate Cancer (2023)